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Abstract
Background: Coronary artery disease is the most prevalent cardiovascular disease. In the United States, 7% of
adults over 20 years of age are estimated to have coronary artery disease. In Brazil, a prevalence of 5 to 8% has
been estimated in adults over 40 years of age, with an increased number of hospitalizations associated with both
stable and acute clinical manifestations; and health care costs have quadrupled in the last decade. To estimate the
direct costs of managing ischemic heart disease patient care in a teaching hospital in Brazil from the perspective of
the service payer, the Brazilian Unified Health System.
Methods: This study was a retrospective cohort study for the identification and valuation of resources used at both
the outpatient and in-hospital levels in a sample of 330 patients selected from the hospital's ischemic heart disease
clinic. Data were collected from computerized hospital records and patients' hospital bills from January 2000 to
October 2015. A bivariate analysis and binary logistic regression were performed with p < 0.05 considered
statistically significant.
Results: The study population consisted of 330 patients with a mean age 61 ± 10 years and a follow-up period of
107 ± 2.6 months; of the patients, 55% were male, 89% had hypertension, 48% had diabetes, and 65% had acute
myocardial infarction. The mean annual cost of outpatient management was US $1,521 per patient. The mean cost
per hospitalization was US $1,976, and the expenses were higher in the first and last years of follow-up. Unstable
angina, revascularization procedures, diabetes, hypertension and obesity were predictors of higher hospitalization
costs (p <0.05).
Conclusion: The cost estimates in this study indicate a high proportion of drug treatment costs in the treatment of
ischemic heart disease. Treatment costs are higher in the first year and at the end of treatment, and some clinical
factors are associated with greater hospital care costs. These results may serve as a basis for the evaluation of
existing public policies and inputs for cost-effectiveness studies in coronary artery disease.
Trial registration: CEP HCPA 11–0460. Ethics Committee of Hospital de Clínicas de Porto Alegre.
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Background
In 2012, cardiovascular disease accounted for 46.2% of
non-communicable chronic disease deaths and 37% of
deaths in people aged under 70 worldwide [1]. In Brazil,
despite a reduction in the number of deaths since the
1990s, cardiovascular disease accounted for 28% of
deaths in 2013 and incurred the highest spending in
hospitalization in the Brazilian Unified Health System
(SUS) in 2009 [2–4].
Coronary artery disease (CAD) is the most prevalent
cardiovascular disease. In the United States, 7% of adults
over 20 years of age are estimated to have a coronary ar-
tery disease diagnosis; by 2030, there will be an increase
in this indicator [5]. In Brazil, a prevalence of 5 to 8%
has been estimated in adults over 40 years of age [6],
with an increased number of hospitalizations associated
with both stable and acute clinical manifestations [6, 7].
Health costs have been increasing since the 1980s,
mainly due to the incorporation of new technologies
and demographic and epidemiological population
transitions. In Brazil, health care costs have quadru-
pled in the last decade, reaching US $125 billion in
2013, of which 44% was paid by public health and
56% by the private sector [8].
The increase in spending on health, the need to bal-
ance public budgets and to seek efficiency in the alloca-
tion of resources, and the requirement of taking into
account social demands in their entirety has led to a
growing number of economic studies to aid in the
decision-making process regarding the implementation
of new public health policies.
Disease cost studies are important in Brazil because
they provide a baseline for complete economic evalua-
tions, such as cost-effectiveness studies. Identifying costs
involves proper planning for data collection to enable
the use of the generated information as an aid for future
studies. In this context, this study aimed to estimate the
direct costs associated with the treatment of ischemic
heart disease at the outpatient and in-hospital levels in a
public teaching hospital from the perspective of the
main service public payer in Brazil, SUS.
Methods
This study was a retrospective cohort study to identify
and value resource use in ischemic heart disease outpa-
tients of the Hospital de Clínicas de Porto Alegre between
January 2000 and October 2015. We used a bottom up
microcosting methodology for 330 patients estimating dir-
ect costs during more than 10 years follow up. The inclu-
sion criteria in this study were outpatients with follow-up
of more than or equal to one year and a minimum of 3
consultations since January 2009. Of the 633 patients
followed up in the ischemic heart disease clinic, 330 met
the inclusion criteria and were included in the study.
Data collection
Forms were developed using REDCap [9] to collect
retrospective data related to ambulatory care protocol
clinical information. The information included CAD
risk factors, medical history and current physical as-
sessment, medication used, hospitalizations, proce-
dures and tests performed during follow-up. Resource
use for outpatient treatment and for hospitalization
were analyzed separately.
Information relative to the following factors were re-
corded on the clinical assessment form: (A) Canadian
Cardiovascular Society (CCS) functional class, (b) previ-
ous diagnosis of unstable angina, myocardial infarction,
stroke, and congestive and valvular heart failure, (c) risk
factors (diabetes mellitus, hypertension, dyslipidemia,
and current and previous smoking), (d) medication use
and (e) physical examination (weight, height, systolic
and diastolic blood pressure, and heart rate).
Quantification of resources
The following factors were quantified during outpatient
treatment: medical appointments, tests, outpatient
catheterization procedures, medications in use, and
transport of the patient to the hospital. Only medical
consultations that took place in the ischemic heart dis-
ease clinic were considered. The number of consulta-
tions performed per patient was recorded.
The following drugs in use were considered in this
study: acetylsalicylic acid, allopurinol, amiodarone,
amlodipine, atenolol, atorvastatin, benazepril, captopril,
clopidogrel, digoxin, diltiazem, enalapril, furosemide, hy-
drochlorothiazide, glibenclamide Isosorbide, losartan,
lovastatin, metformin, metoprolol, nifedipine, omepra-
zole, paracetamol, pravastatin, propranolol, simvastatin,
sustrate, warfarin, and verapamil. The list of drugs that
were considered in this analysis is not exhaustive. The
drugs included in the study were the ones prescribed by
the cardiologists who tended to the patients while the
study was ongoing as well as hypoglycemic drugs. All
drugs were recorded in mg/day. We assumed that the
drugs were purchased by the patients at pharmacies
using their own resources without government subsidies
and were taken with 100% treatment adherence.
The laboratory tests included alanine aminotransferase
(ALT), albuminuria, aspartate aminotransferase (AST),
total calcium, creatine kinase (CK and CK-MB), high
density lipoprotein (HDL) cholesterol, low density lipo-
protein (LDL) cholesterol, total cholesterol, creatinine,
glycemic curve, qualitative urine test (QUT), urinary
sediment test, phosphorus, glucose, glycated hemoglobin,
potassium, C-reactive protein, thyrotropin, triglycerides,
and urea.
Cardiac and imaging tests included were myocardial
scintigraphy (stress and resting), echocardiography,
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stress echocardiography, resting electrocardiography, ex-
ercise test, Holter, ambulatory blood pressure monitor-
ing (ABPM), chest X-ray, carotid and vertebral Doppler
echocardiography, venous color Doppler echocardiog-
raphy, and chest tomography.
The following factors were quantified in terms of hos-
pital treatment: hospitalization days, intensive care unit
(ICU) days, laboratory and diagnostic tests, angioplasty
procedures with or without stent implantation, cardiac
catheterization, and coronary artery bypass surgery per-
formed during hospitalization.
Three pieces of information were evaluated for the
hospitalizations (disease code, treatment code charged
to the hospital account, and the specialty responsible for
the hospitalization). The study included hospitalizations
with International Classification of Diseases and Related
Health Problems (ICD-10) relating to Chapter IX -
Diseases of the Circulatory System (I00 to I99), Chapter
XVIII - Symptoms, signs and abnormal clinical and la-
boratory findings, not classified elsewhere (R00, R07–4,
R53, and R55), Septicemia, unspecified (A41.9), unspeci-
fied Diabetes Mellitus (E14), Transient cerebral ischemic
attacks and related syndromes (G45), Prosthetic device,
implant and cardiac and vascular graft complications
(T82.0 to T82.9), Fitting and adjustment of other exter-
nal prosthetic devices (Z44.8) and presence of implants
and cardiac and vascular grafts (Z95.0 to Z95.9).
Death, hospitalization and coronary artery bypass sur-
gery were defined as major events.
Resource valorization
The study used the SUS reimbursement system to esti-
mate costs. The costs of consultations and tests were
calculated by multiplying the quantity by the unit price
of each resource used in the SUS table.
For pharmacological treatment, a survey of drug prices
was performed in the same physical form across three
pharmaceutical networks, and their mean prices were
calculated. The average price of the medicines was cal-
culated based on the generic version of the drug when-
ever it was available in Brazil. From the list of
medications considered, only 2 drugs do not have the
generic version available in Brazil: benazepril by the
Novartis Laboratory and sublingual isosorbide-5 mono-
nitrate by the Baldacci Laboratory. For patient transport
costs, the price of public land transport in force in
October of 2015 was used by assuming 2 journeys for
residents in Porto Alegre and 4 journeys for residents in
the metropolitan area, in the state interior, and in other
states.
For hospitalization costs, the hospital bill amounts
paid were used and adjusted for inflation by the National
Consumer Price Index (Índice Nacional de Preços
Amplo - IPCA) [10] considering the month of closure of
the hospital bill as the initial date and October 2015 as
the final date.
The total cost of each patient included outpatient care
and hospitalization and was divided by the follow-up
period to obtain the mean annual cost per individual.
The costs were expressed as median values in Brazilian
currency and converted to US dollars at an exchange
rate of 1 Real = US $3.60 (exchange rate of 10/2016).
For the estimated annual hospitalization cost per patient,
analyses were performed to identify potential clinical
predictors of higher cost considering the following vari-
ables: gender, age, CCS functional class, stroke, unstable
angina, myocardial revascularization surgery, myocardial
infarction, diabetes mellitus, dyslipidemia, hypertension,
body mass index, and active and prior smoking status.
Statistical analysis
Descriptive data are presented as absolute and relative
frequencies for categorical variables and as means and
standard deviations or medians and interquartile ranges
(25th and 75th percentiles) for continuous variables. The
Kolmogorov-Smirnov test was used to evaluate the data
normality. The costs are presented as the mean and me-
dian. The cost variables were compared in relation to
clinical predictors using the Mann-Whitney test for data
with non-normal distributions after logarithmic trans-
formation (bivariate analysis). A generalized linear model
analysis (GLM) was performed to evaluate independent
predictors of annual cost per patient. Binary logistic re-
gression was performed to estimate the probabilities of
major events and to establish a relationship with the es-
timated costs. A value of p < 0.05 was interpreted as sta-
tistically significant. To estimate the score, the cost ratio
for significant risk factors was used and the individual
probabilities of the presence of major events were
calculated.
Results
A total of 633 patients were evaluated, of whom 330 met
the inclusion criteria and constitute the study popula-
tion. A total of 54.8% were male, and 51.8% lived in
Porto Alegre. The mean age was 61 years, and the mean
follow-up period in the ischemic heart disease clinic was
107.38 ± 2.62 months. Patients with CCS functional
class I accounted for 73% of the sample, and patients
with CCS class II accounted for 20.6%. There were 31
deaths (9.4%) during the follow-up period, of which 5
were related to concomitant malignancies. The baseline
characteristics of the sample are presented in Table 1.
The use of outpatient resources in the follow-up period
consisted of 9264 consultations, 71,114 laboratory tests,
5697 diagnostic tests and 416 outpatient catheterizations.
On average, there were 28.1 consultations (median 28
and standard deviation 13.11) and 2 catheterizations
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(median 2 and standard deviation 1.44) per patient. The
patients’ travel costs based on a return journey from their
residence to the hospital totaled US $47,955 during the
follow up. On average, the patients used 6 drugs per day,
representing a mean cost of US $6174 (median US $5519)
and a total of $2,037,298 during the period. Drug costs are
shown in Table 2.
The total outpatient costs during the follow-up period
were US $2,432,933 (Table 3), with a mean annual cost
per patient of $854 (median US $765). The greatest
drivers of the outpatient costs were pharmacological
treatment (81%) and imaging tests (7%).
The mean estimated total hospitalization cost during
the follow-up period was US $6104 (median US $4086),
which generated a mean cost per hospitalization of US
$1976 (median US $1710) (Table 4).
Regarding the total in-hospital procedures performed,
catheterizations accounted for 33% (n = 186), angioplas-
ties for 53% (n = 294) and coronary artery bypass sur-
gery for 12% (n = 66). A total of 102 laboratory tests
(median 52) and 11 imaging tests (median 7) were per-
formed on average for each patient hospitalized during
the follow-up period. In total, 26,092 laboratory tests
and 2484 imaging tests were performed during the
follow-up period.
Analysis of the total cost for the SUS showed that the
highest costs occurred during the first year of follow-up;
these costs average US $2865 per hospitalization, with a
median of US $2799. The highest number of admissions
also occurred during this period (Fig. 1).
Considering outpatient and hospitalization costs as a
whole, the estimated total costs were US $3,965,228,
with a mean annual cost per patient of US $1522 and
median of US $1217 (Table 4). In this study, hospital
costs accounted for 38.6% of the total cost of managing
ischemic heart disease and outpatient costs accounted
for 61.4%. The largest driver of costs was expenditure on
drugs, followed by procedures during hospitalization
(Fig. 2).
Significant factors that drove the greatest annual costs
per patient in hospitalization included unstable angina,
angioplasty, prior infarction bypass surgery, diabetes
mellitus, hypertension, and obesity. Male gender and age
were associated with greater hospitalization costs, but
this result was not maintained after the multivariate ad-
justment (GLM) (Table 5).
Because this study involved a specialized outpatient
clinic and a cohort with 10 years of follow-up, 76.7% of
the patients had an event during this period. The esti-
mated total cost for the SUS was assessed in relation to
the likelihood of major events (hospitalization, death,
and coronary artery bypass surgery) and the estimated
annual cost per patient by considering the presence of
significant risk factors in the bivariate analysis. The re-
sults are shown in Figs. 3 and 4.
Discussion
The results of this study offer up-to-date data regarding
the outpatient and hospital management cost of patients
undergoing clinical follow-up in an ischemic heart dis-
ease clinic in a public teaching hospital.
When estimating costs, some economic factors must
be considered in the analysis, such as market prices, in-
flation, depreciation of goods, and opportunity cost [11].
Because this study involved a cohort with a ten-year
follow-up, the amounts received in the years prior to the
analysis were adjusted for inflation. The price tables used
by the SUS were used to estimate the costs, with the
Table 1 Basic population characteristics (n = 330)
Characteristics N (%)
Male gender 181 (54.8)
Mean age (years)* 61 ± 10.3
Acute myocardial infarction 204 (61.8)
Unstable angina 94 (28.5)
Coronary artery bypass surgery 102 (30.9)
Stroke 21 (6.4)
Heart failure 18 (5.5)
Angioplasty 169 (51.2)
Diabetes mellitus 115 (34.8)
Arterial hypertension 277 (83.9)
Dyslipidemia 185 (56.1)
Current smoking 53 (16.1)
Previous smoking 196 (59.4)
Obesity 86 (26.1)
Overweight 139 (42.1)
Regular physical activity 109 (33.0)
CCS class
I 241 (73.0)
II 68 (20.6)
III 17 (5.2)
IV 4 (1.2)
Patient origin
Porto Alegre 171 (51.8)
Metropolitan region 122 (37)
Interior 35 (10.6)
Other states 2 (0.6)
SBP* 138.7 (80–230)
DBP* 82.6 (50–160)
Follow-up time** 107.38 ± 2.62
*expressed as the mean and interquartile range. **expressed in months
CCS = Canadian functional class; SBP = Systolic blood pressure; DBP = Diastolic
blood pressure
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exception of drug prices. The prices used by the SUS do
not reflect the true costs of the intervention, rather re-
imbursement values, but represent the closest ones.
They can be considered the opportunity cost of each
system, which is considered by some authors to repre-
sent the real economic value of a resource used to per-
form an intervention [12, 13]. For the drugs price, we
used the average price of the drugs; the estimates would
Table 2 Unit prices from the SUS table
Resources US$ price
Consultations 2.10
Hospitalization days* NA
ICU III days 141.29
Procedures**
Coronary Angioplasty 712.25
Primary Coronary Angioplasty (including catheterization) 1303.28
Coronary Angioplasty with stent implantation 1277.39
Coronary Angioplasty with two stents implantation 2090.00
Cardiac catheterization 365.84
Myocardial Revascularization with extracorporeal use 3679.46
Diagnostic tests
Myocardial scintigraphy with dipiridamol 113.48
Stress myocardial scintigraphy 113.48
Resting myocardial scintigraphy 106.41
Echocardiogram 11.09
Stress echocardiogram 45.83
Electrocardiogram 1.43
Exercise test 8.33
Holter 8.33
Ambulatory Blood Pressure Monitoring 2.80
BP Chest X-ray 1.81
Venous color Doppler ultrasound 11.00
Laboratory tests
Calcium 0.51
CK 1.02
CK-MB 1.14
HDL and LDL cholesterol 0.98
Total cholesterol 0.51
Creatinine 0.51
Glycemic curve 1.01
Qualitative urinary test 1.03
Phosphorus 0.51
Glucose 0.51
Glycosylated hemoglobin 2.17
Potassium 0.51
C Reactive protein 0.79
Glutamic-oxaloacetic transaminase (GOT) 0.56
Glutamic-pyruvic transaminase (GPT) 0.56
Thyrotropin 2.49
Triglycerides 0.98
Troponin 2.50
Urea 0.51
Generic Drugs***
Acetylsalicylic acid 100 mg 0.06
Table 2 Unit prices from the SUS table (Continued)
Allopurinol 100 mg 0.08
Amiodarone 200 mg 0.26
Amlodipine 5 mg 0.37
Atenolol 50 mg 0.22
Atorvastatin 20 mg 0.73
Captopril 12.5 mg 0.16
Captopril 25 mg 0.22
Captopril 50 mg 0.46
Clopidogrel 70 mg 1.45
Digoxin 0.25 mg 0.10
Diltiazem 60 mg 0.16
Enalapril 5 mg 0.24
Enalapril 10 mg 0.21
Enalapril 20 mg 0.36
Furosemide 40 mg 0.12
Hydrochlorothiazide 25 mg 0.20
Glibenclamide 5 mg 0.08
Isosorbide 10 mg 0.08
Losartan 50 mg 0.34
Lovastatin 20 mg 0.41
Metformin 850 mg 0.23
Metoprolol 100 mg 0.19
Nifedipine 10 mg 0.25
Omeprazole 20 mg 0.25
Paracetamol 500 mg 0.16
Pravastatin 10 mg 0.44
Propranolol 40 mg 0.06
Propranolol 80 mg 0.09
Simvastatin 10 mg 0.63
Simvastatin 40 mg 0.51
Sustrate 10 mg 0.13
Warfarin 5 mg 0.10
Verapamil 80 mg 0.20
Non-generic drugs***
Benazepril 5 mg 0.54
Sublingual Isosorbide-5 mononitrate 0.11
*Inpatient stay in the SUS are included in the payment for the treatment
performed. ** Includes normatives income. *** price for one tablet
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be more accurate if it were possible to identify the
amount paid by the government for the medication.
However, in the Brazilian government’s health database,
called DATASUS, this information is not available.
In Brazil cost management accounting in the health
area is a rather recent theme and institutions are still de-
veloping initiatives to know the real costs of patient care.
In our hospital, there is no cost management system at
the moment and thus, we cannot accurately state what
percentage of the costs we find represents the real costs
incurred. Since 2008, the readjustments of the Brazilian
Health System reimbursements do not reflect Brazilian
inflationary indices such as the National Broad Con-
sumer Price Index (IPCA) and the National Consumer
Price Index (NCPI). According to the Brazilian Federal
Council of Medicine, in the performance of a coronary
angioplasty with stent implantation this gap varies be-
tween 39% for the IPCA and 40% for the INPC.
Although previous studies are scarce in the Brazilian
literature, some have described the management costs of
cardiovascular disease patients. Below, some of these
studies are discussed, and the results prior to 2015 have
been updated for inflation and are presented in this for-
mat for comparisons.
The mean annual cost per outpatient in the SUS was
US $854 (median US $765); this finding was similar to
the result reported by Ribeiro et al. [7] in a study con-
ducted in 2002, which reported an annual per patient
expenditure of US $779 (median US $760) with the same
cohort of patients, and by Azambuja et al. [14], who esti-
mated a mean annual cost of US $875 for cases of severe
cardiovascular disease.
In terms of the composition of outpatient costs,
spending on drug treatment was responsible for the
highest expenditure. Regarding the mean annual cost of
drugs, the studied sample showed values similar to US
$830 found by Araújo et al. in heart failure patients [15].
This expenditure as a proportion of the total outpatient
cost (81%) was higher than that found by Ribeiro et al.
[7] (80%). This finding is consistent with the reality of
Brazilian health care and may reflect the entry of new
drugs with higher prices into the market, an increasing
number of concomitant cardiovascular diseases, and cu-
mulative price inflation. The cost results presented are
similar to those of 10 years ago and we consider that this
similarity can be partly explained by the gap in the cor-
rection of the Brazilian Health System reimbursements.
For example, the value of the medical consultation for
reimbursement is US $2.10 since 2005; similarly, several
laboratory tests requested in the routine care of patients
with ischemic heart disease remain unchanged at US
$0.51. Another example, the value of stress scintigraphy
Table 3 Outpatient costs during the follow-up period in US$
Consultations Laboratory tests Diagnostic tests Drugs Transport Catheterization Total outpatient cost
N 330 326 325 330 330 208 330
Mean 58.88 178.92 497.91 6.173.63 145.32 519.73 7372.53
Median 58.72 149.96 407.31 5.518.92 74.03 341.51 6539.51
Minimum 6.29 10.58 7.15 0.00 7.22 170.76 275.32
Maximum 159.39 913.76 1742.44 23,560.92 4613.83 2788.11 26,193.39
Total 19,428.67 58,328.71 161,819.60 2,037,297.67 47,954.91 108,104.27 243,293.83
Table 4 Hospitalization costs*
Mean cost per hospitalization US$ value
N 251
Mean 1976.21
Median 1710.39
Standard deviation 1231.69
Minimum 103.82
Maximum 11,014.21
Cumulative cost of hospitalizations
Mean 6104.76
Median 4086.02
Standard deviation 5843.72
Minimum 103.82
Maximum 38,890.29
Total 1,532,293.84
Costs per patient considering the outpatient and hospitalization basis
Mean 12,015.84
Median 9726.93
Standard deviation 8134.67
Minimum 275.32
Maximum 59,437.76
Annual cost per patient
Mean 1521.54
Median 1217.10
Standard deviation 1171.49
Minimum 237.79
Maximum 8171.83
*Includes tests, procedures, specialist materials, ICU days and fees when incurred
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found by Ribeiro was US $93.33; using by the IPCA
index, it should be equivalent to US $167.63 (a variation
of 79.61%) in this study. However, the reimbursement
system only pays US $113.48 (a variation of 21.59%).
This study considered that patients paid for 100% of the
drugs and that there was 100% drug adherence, which
might have led to overestimation of the total costs. In-
deed, hypertension, diabetes, and dyslipidemia drugs are
provided free in Primary Health Care Units (PHCUs) to
public health system users, and there are government
subsidies when these drugs are purchased by the private
health system users as part of the National Pharmaceut-
ical Assistance Policy [16]. Regardless, patient accessibil-
ity to this program was not ascertained in this study. In
relation to treatment adherence in Brazil, Tavares et al.
[17] found a high rate of adherence used to treat high
blood pressure, ranging from 71% in the North to 84%
in the South. Santos-Pinto et al. [18] analyzed the
Popular Pharmacy Program aimed at private system
users and estimated that approximately 70% of users in
the North and Northeast who could obtain the drugs for
free in the PHCUs acquired them from the Popular
Pharmacy Program due to access problems in the
PHCUs.
The mean cost to the SUS of each hospitalized patient
of US $1976 was similar to the amount reported by
Teich [4] (US $2005) in a study of acute coronary
syndrome.
The analysis of the total cost to the SUS for each pa-
tient during the period suggests that the total costs were
Fig. 1 Total cost to the SUS per year of follow-up (median)
Fig. 2 Individual costs as a proportion of the total cost during follow-up
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higher in the first year and at the end of follow-up, but
it was not possible to establish an expenditure distribu-
tion pattern. When considering the major events in this
cohort (n = 1021), the clinical variables that were
predictive of increased costs were unstable angina,
angioplasty, coronary artery bypass surgery, diabetes
mellitus, obesity, and hypertension, with hospitalizations
and readmissions responsible for 93% of all events.
The higher number of hospitalizations during follow-
up is consistent with literature, which shows re-
hospitalization rates of over 30% during the first year
of follow-up [16, 19]. As expected, the greater prob-
ability of events was associated with higher costs, which
underscores the finding that the main drivers in this re-
gard are related to the presence of severity markers, and
consequent instability and need for hospitalization.
In this study, the outpatient costs were proportion-
ately higher than the hospitalization costs in relation to
the total cost primarily due to the drug expenditure.
This result is different from the results found in the lit-
erature. The study with one year of follow-up con-
ducted by Araujo [15] reported costs of 40% for
hospitalization and 39% for medication. This difference
may have been due to the data collection method used
when quantifying drug use. In the study by Araújo,
drug prices were calculated using the Brasíndice table
in 2002. The Brasíndice table was a table published by
a specialized company that had the price of drugs sold
in Brazil, including the factory price and the maximum
price to the consumer, plus taxes. Since May 2009, by
resolution of the Regulation Chamber of the Brazilian
Medicines Market, it is not allowed to divulge the max-
imum price of drugs to the consumer. We highlight
that the Araújo study was carried out in 2002 with a
cohort of 70 patients and used the methods of identify-
ing the cost items and cost tables available at the time
to estimate the actual costs of one year of treatment,
including applying an overhead rate to the cost compo-
nents. However, Araujo estimated the cost of
hospitalization through the prospective analysis of 3 pa-
tients to identify the use of resources and establish the
average cost of a day of hospital stay (top-down micro-
costing). Today the methods used by Araujo could be
considered a mix of the bottom-up and the top-down
microcosting approaches. The top-down approach usu-
ally produces higher values than the bottom-up ap-
proach. Our study used the bottom-up micro-costing
approach for identifying and quantifying all cost com-
ponents. We believe that the differences found may also
be influenced by the different methodological ap-
proaches used. In the United States, Sieck [20] esti-
mated hospital costs as being responsible for 60% and
drugs for 10% of direct costs in patients with congestive
heart failure. Dunlay et al. [21] reported that 77% of
Table 5 Clinical predictors of the annual cost per patient
Male Female P*
Mean Median Mean Median
Annual cost per
patient
1556.14 1171.74 1454.52 1298.85 0.884
≤74 years ≥ 75 years
Mean Median Mean Median
Annual cost per
patient
1508.29 1212.88 1649.38 1272.95 0.809
Stroke No Stroke
Mean Median Mean Median
Annual cost per
patient
1727.86 1301.13 1507.52 1199.09 0.158
Unstable angina No Unstable angina
Mean Median Mean Median
Annual cost per
patient
1742.73 1490.25 1433.45 1119.83 0.002
CABS No CABS
Mean Median Mean Median
Annual cost per
patient
1649.55 1422.75 1464.28 1156.82 0.01
AMI No AMI
Mean Median Mean Median
Annual cost per
patient
1578.52 1155.48 1429.29 1260.28 0.562
Diabetes No Diabetes
Mean Median Mean Median
Annual cost per
patient
1781.96 1500.19 1382.25 1144.14 < 0.01
Dyslipidemia No Dyslipidemia
Mean Median Mean Median
Annual cost per
patient
1475.45 1158.71 1580.36 1265.95 0.271
Hypertension No Hypertension
Mean Median Mean Median
Annual cost per
patient
1568.30 1232.89 1277.17 1183.72 0.03
BMI ≤ 29.9 BMI ≥ 30
Mean Median Mean Median
Annual cost per
patient
1451.13 1145.89 1629.54 1498.74 0.011
Current smoking No Current smoking
Mean Median Mean Median
Annual cost per
patient
1398.59 1059.38 1558.75 1179.43 0.838
Previous smoking No Previous smoking
Mean Median Mean Median
Annual cost per
patient
1678.31 1059.38 1523.99 1177.12 0.545
Heart failure No Heart failure
Mean Median Mean Median
Annual cost per
patient
2323.57 1.482.99 1475.28 1209.04 0.179
Angioplasty No Angioplasty
Mean Median Mean Median
Annual cost per
patient
1832.63 1491.66 1195.00 976.29 < 0.01
*Mann-Whitney test
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costs in heart failure were incurred during
hospitalization. The difference between our results and
those of international studies may be that the
hospitalization figures do not account for Brazilian in-
flation rates. Thus, the prices charged were below infla-
tionary correction for the period. Another factor that
may have contributed to this result was the reduction
in the cost of orthotics and prostheses (stents) in recent
years. In early 2000, the costs of these products were
high, but the costs have subsequently reduced due to
the entry of a wide range of products from the Indian
and Chinese markets into the Brazilian market [22].
Moreover, in the past, stents were acquired by the hos-
pitals with the insertion of a profit margin in the trans-
fer to the hospital account but, currently, are acquired
directly by the health plans, and the supplier is paid
directly.
In the bivariate analysis, clinical factors such as
heart failure, acute myocardial infarction, dyslipid-
emia, and stroke were not confirmed as major cost
predictors. This finding confirmed the results of other
studies [14, 23, 24]. Diabetes mellitus and unstable
angina were the major cost drivers at both the out-
patient and in-hospital levels. The association of the
number of major events with costs can be explained
by the long follow-up period of this cohort and the
number of hospitalizations. A study of heart failure
patients showed that 51.2% of the patients return to
the emergency room between 1 and 12 times over a
one-year period [25].
Considering the 2012 demographic census for the
population over 18 years is 9,548,247 people and a
prevalence of 7% for ischemic heart disease, the annual
direct costs to the SUS for ischemic heart disease would
be at least US $3.66 billion. This figure is similar to the
figure reported by Teich [4].
Some limitations of this study should be mentioned.
Costs related to drugs were assumed to be constant
throughout the follow-up period, and the existence of
subsidies from governmental pharmaceutical assistance
programs and treatment adherence were not considered,
which may have caused the share of these costs in the
analysis to have been disproportionately high. Another
limitation is that the costs in this study were calculated
based on the value of the service provided and did not
include institutional operating costs. This approach may
have led to underestimation of the presented costs.
Fig. 3 Mean annual cost per patient considering the number of
major events
Fig. 4 Median annual cost per patient according to significant clinical predictors
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Conclusion
This study showed that the direct costs of longitudinal
ischemic heart disease treatment were high and were
primarily driven by chronic pharmacological treatment
and days of hospitalization; through out a 10-year period
the costs were higher in the first year and the last years
of follow-up.
In 2014, the per capita income of the Brazilian popula-
tion was US $292. Thus, the cost of drugs in this study
suggests the need to expand the National Pharmaceutical
Assistance Policy to include drugs related to coronary
heart disease and to review the drug distribution policy in
the PHCUs to provide access to drugs and reduce morbid-
ity and mortality.
Data from this study could help to define health care
policies for ischemic heart disease patients in terms of
the allocation of human resources (physicians and care
staff ), physical resources (admissions, tests, and drugs),
and appropriate financial planning.
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